Image

Brief Exposure and Exercise for PTSD.

Brief Exposure and Exercise for PTSD.

Recruiting
18-64 years
All
Phase N/A

Powered by AI

Overview

The goal of this clinical trial is to learn if 8 sessions of brief exposure and exercise therapy works to treat Post Traumatic Stress Disorder (PTSD) in adults. This study will also learn if participants think brief exposure and exercise therapy is a good and doable treatment. and The main questions it aims to answer are:

  • Do participants find brief exposure and exercise an acceptable and feasible means of treatment for PTSD?
  • Does brief exposure and exercise decreases of the severity of PTSD symptoms?

Participants will:

  • Complete weekly questionnaires for 10-14 weeks.
  • Attend 8 twice weekly exposure therapy and exercise sessions for 4 weeks.

Description

A community sample (n=6) of adults with PTSD will receive eight sessions of standardized brief exposure therapy with six sessions of imaginal exposures and aerobic exercise. This clinical trial will be the first study demonstrate the effectiveness of an exposure-only therapy and exercise treatment by isolating and targeting safety learning using imaginal exposures. This approach will address gaps in the literature by demonstrating treatment effectiveness, mechanistic engagement, and patients' perceptions of a brief imaginal exposure treatment combined with aerobic exercise. Addressing these gaps through a preliminary clinical trial that establishes feasibility and treatment effectiveness is a necessary first step before exerting substantial time and money on a large-scale clinical trial.

Aligned with an experimental therapeutics approach, the proposed study will take advantage of single-case experimental design (SCED) to explore changes in PTSD symptom severity and exposure therapy mechanisms (i.e., belief change, experiential avoidance, and emotional intensity) within each participant. SCEDs are parsimonious research designs that are ideal for investigating mechanisms and the effectiveness of interventions. SCEDs use each subject as their own control, resulting in high internal validity and the ability to examine effect sizes across subjects.

Upon referral to the study, participants will complete a brief battery of self-report questionnaires to screen for eligibility. Likely eligible participants, determined by the prescreening, will be given a link to schedule an intake with PI or other graduate student research personnel to complete informed consent and assessments to evaluate inclusion/exclusion criteria. Eligible participants will then be randomized to either a 3, 4 or 5 week baseline period, where participants will complete weekly self-report questionnaires to assess PTSD symptoms and exposure therapy mechanisms. Participants fill out a questionnaire battery before, during, and after treatment resulting in a total of 10-14 weeks of self-report assessments. After the baseline assessment phase, participants will complete the first session of PE, which focuses on psychoeducation and treatment planning, six sessions of imaginal exposures and exercise, and a final PE session discussing relapse prevention and future directions. During the six imaginal exposure sessions (sessions 2-7), participants will complete 20 minutes of imaginal exposure to traumatic memories, 10 minutes of emotional processing, and then 20 minutes of moderate-intensity exercise (i.e., 70-75% of MHR) on a stationary bike with 3 minutes of warmup and 2 minutes of cool-down. Proximal measures for exposure mechanisms will be assessed during treatment sessions (e.g., subjective units of distress) to align with distal measures of exposure therapy, which are assessed in the weekly self-report batteries. Following completion of the treatment, participants will be asked to provide satisfaction ratings on the treatment.

PTSD symptom severity will be assessed weekly to investigate treatment efficacy (Aim 1). Acceptability will be evaluated using a self report patient satisfaction questionnaires (Aim 2). Adherence to the treatment protocol will be used to characterize feasibility (Aim 3).

Eligibility

Inclusion Criteria:

  • Provide informed consent and are willing to participate in therapy sessions twice weekly, which include moderate-intensity aerobic exercise.
  • Participants must be adults aged 18-64 meeting the criteria for PTSD within the past month, who are not currently receiving treatment from other psychotherapy or are on unstable psychiatric medication (i.e., less than four weeks of psychiatric medication).
  • Participants should be able to engage in 25 minutes of moderate-intensity aerobic exercise (i.e., 70-75% of max heart rate).
  • Participants must be able to speak and read English fluently to participate in the current study.

Exclusion Criteria:

  • Participants who endorse health condition(s) that would prevent moderate exercise.
  • Participants who endorse (i.e., "yes") any items on the Physical Activity Readiness Questionnaire (PARQ) that is not controlled or managed.
  • Participants with any injuries to the lower extremities that may hinder riding an exercise bicycle.
  • Psychiatric exclusion criteria include recent (within the past three months) severe use disorder(s), high risk for suicide (i.e., plan, intent, or recent attempt), mania, or psychotic symptoms unrelated to PTSD symptoms.
  • Participants currently seeking or undergoing any other trauma-focused psychotherapy treatment.

Study details
    PTSD - Post Traumatic Stress Disorder

NCT07080606

Troy Hubert

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.